Post by
SPCEO1 on May 06, 2022 9:19am
Meeting with management
Along with three other large shareholders, I had a call yesterday afternoon with the CEO, CFO and CMO. I don't have a lot of time right now to summarize it well but it was an encouraging call. On cancer the CMO said the results are tracking close to what they expected from the preclinical work. I will post more later but the main takeaway is that cancer seems to be on a good path.
Comment by
longterm56 on May 06, 2022 9:38am
Sorry for being cynical, but I think the "main takeaway" is that they were campaigning for votes for the Board. A meeting with you "along with three other large shareholders" 5 days before the AGM? Seriously? -LT
Comment by
stockman75 on May 06, 2022 9:48am
You are cynical for good reason. I voted against all board members to send a message. I have some trust issues with the board. I think the science is solid and a lot of promise.
Comment by
Garp1 on May 06, 2022 12:32pm
Completly agree with you.
Comment by
palinc2000 on May 06, 2022 9:39am
This is fantastic news but how many shares do we need to hold to get access to such info?
Comment by
SPCEO1 on May 06, 2022 10:07am
Zero shares since I report to you here about it. But the group on the call collectively controls about 14% of the shares.
Comment by
Bucknelly21 on May 06, 2022 10:39am
Lets hope the science can overcome the endless shortcomings dealing with the markets...
Comment by
palinc2000 on May 06, 2022 11:49am
So tell me what being in line with .......means.
Comment by
SPCEO1 on May 06, 2022 2:01pm
He thinks whatever side effects TH-1902 has will dissipate quickly between cycles and will not have the cumulative effect that docetaxcel has. Hopefully that proves to be true.
Comment by
qwerty22 on May 06, 2022 2:08pm
Yep, one of the things I meant to mention but missed out. That seems like a fairly wild claim at this point in time. Maybe patient #2 has reached 10 cycles if you include the early low doses, would seem possible. IDK.
Comment by
SPCEO1 on May 06, 2022 4:10pm
I will take a stab at this but you should probably hope one of scientific teamwill weigh in to get a decent answer. See below in red
Comment by
jeffm34 on May 06, 2022 5:33pm
treating advanced cancers should be an advantage for TH1902. A lot of those cases will have developed resistance which TH1902 might be able to overcome and also the sortilin expression is higher in advanced cancers.
Comment by
jfm1330 on May 06, 2022 10:33am
Thanks for sharing the info. It's awfully long and beyond initial timeline, but I share your sentiment that they will end up with something.